Galapagos NV (GLPGa)

Overview

Galapagos NV is a biotechnology company specializing in the development of innovative medicines that primarily target oncology and immunology. The company is actively engaged in clinical trials and has a strong presence in the United States and Europe. Founded in 1999 and headquartered in Mechelen, Belgium, Galapagos NV leverages its expertise in biomedicine to advance a robust pipeline of therapies aimed at treating various cancers. The company also engages in collaborative agreements with prominent organizations such as Gilead Sciences, Inc. and AbbVie S.à r.l, bolstering its position in the biopharmaceutical sector.

Products and Services

• GLPG3667

  This product has successfully completed a Phase 1b trial and represents a significant advancement in the company's pipeline. Its mechanisms and potential efficacy are currently under further evaluation, with expectations for future phases of clinical trials.

• GLPG5101

  A CD19 CAR-T product candidate designed to be manufactured at the point-of-care, GLPG5101 is currently undergoing a Phase 1/2 trial specifically focused on patients with relapsed/refractory non-Hodgkin lymphoma. This innovative approach aims to enhance the treatment of this particular cancer type.

• GLPG5201

  Similar to GLPG5101, GLPG5201 is another CD19 CAR-T product candidate that is also produced at the point-of-care. It is in the Phase 1/2 trial stage targeting relapsed/refractory chronic lymphocytic leukemia, indicating Galapagos NV's commitment to addressing various forms of hematological malignancies.

• GLPG5301

  This product is a BCMA CAR-T candidate that is manufactured at the point-of-care as well. Currently in Phase 1/2 trials for relapsed/refractory multiple myeloma, GLPG5301 exemplifies the company's focus on pioneering treatments for complex cancer conditions.